EAPH News 01/09/2017 - 0.0273

Message Board

Previous

| Next

Post# of 273249

(Total Views: 1360)

Posted On: 01/09/2017 6:55:15 PM

Posted By: Stock_Tracker

Easton Pharmaceuticals, Inc. $EAPH News
Last updated 01/09/2017 - 0.0273

Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico's Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter

Jan 04, 2017
OTC Disclosure & News Service

-

Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of First Purchase Order For Mexico's Launch for Gynofit -- Lactic Acid Gel Treatment From Gedeon Richter

TORONTO, ON--(Marketwired - Jan 4, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), along with its partners BMV Medica and its host Ackerman Pharma, announce receipt of initial purchase order for the Gynofit Lactic Acid Gel Treatment from Gedeon Richter for their product launch in Mexico slated for this February.

As per its recently announced distribution agreement with Gedeon Richter, Easton / BMV and their host laboratory, Ackerman Pharma, have received an initial purchase order for their in-licensed Gynofit Lactic Acid Gel Treatment with delivery from Switzerland expected later this month, and subsequent delivery to Gedeon Richter in Mexico for an expected February product launch. This agreement coincides with its recent distribution agreement executed with Windsor Pharmaceuticals for Central America which is pending regulatory approval.

"This PO represents the beginning towards delivering sales in 2017 and beyond as we slowly initiate launching our products throughout the territories we have received approval in," stated Evan Karras, CEO of Easton Pharmaceuticals. Mr. Karras further commented, "We expect sales to slowly grow and becoming very robust over the coming years as this natural treatment for Bacterial Vaginosis will be marketed as a natural alternative to antibiotics to successfully treat vaginal infections and also marketed to maintain optimal vaginal flora."

"Gynofit" is a natural product treatment for women diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. As previously announced, the agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing plan for Gynofit and its success, which Easton / BMV and Gedeon Richter believe will steadily drive sales in Mexico over the next three years and beyond.

For More Detailed Information on Gedeon Richter Plc Visit:
http://www.richter.hu/en-US/Pages/default.aspx

In Other Developments
In keeping with Easton's mission towards sales in Mexico and other parts of Latin America from its line of acquired licensed products, Easton, through the efforts of BMV Medica, have been in discussions with multi-national pharmaceutical giant, Bayer of Germany, and its US offices for Easton's (VS-Sense) product, currently licensed from CommonSense of Israel for the country of Mexico and other territories. Bayer currently markets and sells the product under its own white labeling in Europe and Brazil. No agreement acceptable to both parties has yet been finalized after many months of negotiations. If no satisfactory agreement is reached, Easton and BMV may move forward with alternate plans and initiatives which may involve other partners or the deployment of its own sales network. Easton and BMV have entered into discussions for the acquisition or merger of BMV Medica by Easton, which would include BMV's other line of licensed products. In other news, other late stage negotiations are ongoing in other sectors including medical marijuana which it hopes to shortly disclose.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products from CommonSense of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine's Ontario, Canada.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.bmvmedica.net
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"

. In particular, when certain words or phrases such as "hope," "positive," "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3084811
Easton Pharmaceuticals Inc.
Contact: Evan Karras
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

Copyright © 2016 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Easton Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement With Women's Health-Focused Multi-National European Pharma Company for Its VS-Sense, AL-Sense and Gynofit Products

May 10, 2016
OTC Disclosure & News Service

-

Easton Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement With Women's Health-Focused Multi-National European Pharma Company for Its VS-Sense, AL-Sense and Gynofit Products

TORONTO, ON--(Marketwired - May 10, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH), together with their commercial alliance partner BMV Medica SA de CV announces it has initiated partnership negotiations for Mexico and Latin American Sales & Marketing of its suite of women's health products with a multi-national Europe-based Pharma company, currently operating in over 38 countries world-wide.

Easton and its partner BMV Medica S.A de C.V have been in formal discussions over the last several months with a Europe-based Multi-National Pharma company who currently has a successful foothold within 38 countries, including Mexico, with specialized Women's Health products. The negotiations have progressed well with interest being high, which has now resulted with both companies moving toward signing a final agreement whereby this company would use its large marketing and distribution resources to take over and spearhead all marketing and distribution of Easton/BMV's VS-Sense, AmnioSense and Gynofit products beginning with Mexico. A final agreement would most likely be executed with the products being launched in stages starting with Gynofit as its first product launch. The regulatory approvals for the VS-Sense and AL-Sense products from the Mexican Ministry of Health is imminent with Gynofit already approved for sale. Although Easton is not at liberty at this time to disclose terms or names, the European multi-national company currently has sales in the Billions of Dollars throughout 38 countries. A partnership with such a company would provide Easton Pharmaceuticals with a significant increase in projected sales than if Easton was to proceed alone. Current projections from the European based company have sales for Gynofit alone at $7,000,000 within 12 months of product launch.

Easton/BMV were notified through Ackerman Pharma, the filing of its patented, point-of-care, VS-Sense Diagnostic test through "fast-track" third-party authorized reviewer Defi Latina Healthcare, S.A. de C.V. for regulatory approval in Mexico. Since submission, Defi Latina -- one of only few authorized third-party reviewers licensed by the Ministry of Health in Mexico to review and pre-approve Regulatory dossiers prior to submission -- has and continues to undergo a detailed review of the regulatory dossier for VS-Sense, a unique point-of-care vaginal discharge diagnostic test called VagiSan in Mexico. VagiSan is the brand Easton/BMV plan to launch in Mexico and Latin America, and is the same product Bayer Pharmaceuticals had licensed and launched recently in Europe under its brand Canestest, and Prestige Distribution in the US has launched under its brand Monistat, with multi-million dollars in sales.

In Mexico, the "fast-track" review process through authorized third-party reviewers can speed up approval times from several years to a few short months if the regulatory dossier is complete. Easton/BMV have worked diligently over recent months with the manufacturer CommonSense LTD of Israel, to ensure a complete dossier is in place, and expect an approval to be granted before the planned launch date of third quarter, 2016.

Prior to the VS Sense Diagnostic test regulatory filing submission, Easton/BMV Medica announced a first-order of the CommonSense products with the total number of units ordered at 230,000 -- 90,000 of the VS-Sense and 140,000 of the AmnioSense -- enough product for launch and three-six months of sales. The AmnioSense diagnostic test as well as the Gynofit bacterial vaginosis treatment are already approved in Mexico through third-party consultants, and these Marketing Authorizations (MAs) are being transferred to Easton/BMV so all three products can be launched at the same time. The European multi-national pharma company anticipates placing an initial order for Gynofit once the final agreement has been executed.

Easton/BMV anticipate the bulk of its sales initially from the Obstetrician/Gynecologist community in Mexico and have already received their first orders following the presentation of these new products this past November at the OB/GYN conference in Acapulco, attended by approximately 4,000 of the 7,000 gynecologists in Mexico.

The Amnio-Sense diagnostic product currently approved for sale in Mexico is owned exclusively for Mexican sales by Easton's partner BMV Medica, but Easton owns together with BMV the rest of Latin America sales, and Easton is in high level discussions with BMV to include AmnioSense for Mexico in the agreement currently in place.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica and owns 50% of the exclusive distribution in Mexico and Latin America for patented women's diagnostic products and two generic cancer products. Easton has made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system for the medical marijuana and other industries. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"

. In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Easton Pharmaceuticals
Evan Karras
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

Copyright © 2016 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Easton Pharmaceuticals and Partner BMV Medica Announces Regulatory Filing of Its Patented Women's Health Diagnostic Product, VS-Sense for the Mexico Market, Provides Update on Generic Cancer Drugs, Paclitaxel, Docetaxel

Feb 16, 2016
OTC Disclosure & News Service

-

Easton Pharmaceuticals and Partner BMV Medica Announces Regulatory Filing of Its Patented Women's Health Diagnostic Product, VS-Sense for the Mexico Market, Provides Update on Generic Cancer Drugs, Paclitaxel, Docetaxel

TORONTO, ON--(Marketwired - Feb 16, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH), together with their commercial alliance partner Ackerman Pharma, announces filing of patented, point-of-care, VS-Sense Diagnostic test through "fast-track" third-party authorized reviewer DefiLatina Healthcare, S.A. de C.V. for regulatory approval in Mexico, provides update on generic cancer drugs Paclitaxel and Docetaxel initiatives.

Over the next few weeks Defi Latina -- one of only a few authorized third-party reviewers licensed by the Ministry of Health in Mexico to review and pre-approve Regulatory dossiers prior to submission -- is undergoing a detailed review of the regulatory dossier for VS-Sense, a unique point-of-care vaginal discharge diagnostic test called VagiSan in Mexico. The "fast-track" review process through authorized third-party reviewers can speed up approval times from several years to a few short months if the regulatory dossier is complete. Easton / BMV have worked diligently over recent months with the manufacturer CommonSense LTD of Israel, to ensure a complete dossier is in place, and expects approval to be granted before the planned launch date of April 2016.

Prior to the VS Sense Diagnostic test regulatory filing submission, Easton / BMV Medica announced a first-order of the CommonSense products with the total number of units ordered at 230,000 -- 90,000 of the VS-Sense and 140,000 of the AmnioSense, enough product for launch and three - six months of sales. The AmnioSense diagnostic test as well as the Gynofit bacterial vaginosis treatment are already approved in Mexico through third-party consultants. Easton's partner, BMV Medica is in the process of having the Marketing Approvals (registrations) transferred to BMV, so all three products can be launched at the same time. Easton / BMV will be placing an initial order for Gynofit with the Swiss manufacturer over the next few weeks.

Easton / BMV anticipate the bulk of its sales initially from the Obstetrician/Gynecologist community in Mexico and have already received its first orders following the introduction of these new products this past November at the OB/GYN conference in Acapulco, attended by approximately 4,000 of the 7,000 gynecologists in Mexico.

The Amnio-Sense diagnostic product currently approved for sale in Mexico is currently owned exclusively by Easton's partner BMV Medica, but Easton is in high level discussions with BMV to include AmnioSense for Mexico in the agreement currently in place, since AmnioSense is already part of the agreement for the rest of Latin America.

Easton expects to shortly announce and provide positive updates on its 2 generic cancer drug initiatives for the Mexico market for approved drugs Paclitaxel and Docetaxel from Canadian Pharma company Biolyse.

BioLyse Pharma, Generic Cancer Drugs Paclitaxel, Docetaxel

Easton / BMV have acquired licensing and distribution rights from Canadian Drug Manufacturer BioLyse Pharma for generic cancer drugs Docetaxel and Paclitaxel for Mexico and Latin America. Following unforeseen delays regarding the dossier and documentation received, Ackerman Pharma has provided a positive update on the regulatory filing towards the Ministry Of Health approval for the generic cancer drugs "Paclitaxel" and "Docetaxel" from St. Catharines, Ontario based Biolyse Pharma Corporation, where it believes through DEFI Latina, a government authorized third-party reviewer, the approval process is expected to be approved and ready for sale by June 2016. The country of origin for the generic cancer drugs is Canada, believed to be one of the top six in the World -- along with the USA, Britain, Australia, France and Germany. Mexican Health Authorities traditionally have very few issues with pharmaceutical products manufactured in these countries and believes a fast track approval is possible with purchase orders and sales to shortly follow. The majority of sales in Mexico will be to the Mexican government hospitals and institutions. As Canada is part of the North American Free Trade Agreement (NAFTA), Canadian-manufactured pharmaceuticals qualify for the national tender program in Mexico, providing a major advantage over other non-NAFTA manufacturers. The "Docetaxel" market in Mexico is by itself worth tens of millions of dollars annually, and BMV expects to be able to garner 20% of that within a year of launch, growing to 30% within three years. The total generic cancer drug market in Mexico represents hundreds of millions of dollars.

Mr. Michael Ackerman, President of Ackerman Pharma stated: "We are aggressively expanding our product and sales channels, and with the addition of these first two generic cancer drugs manufactured by Biolyse Pharma, we are working towards approval in Mexico for later this year with BMV Medica and Easton Pharmaceuticals."

Amnio-Sense Amniotic Fluid Diagnostic Test Approval

Easton Pharmaceuticals and its partner BMV have the rights to the approved amniotic fluid leak test for rest of Latin America, and are in the process of final packaging for the Latin American market under the EvaPro brand. Sales could begin immediately once commercial alliances have been established in the region. These exclusive licensing rights were jointly purchased by Easton and BMV Medica from Israel-based Common Sense Inc. on a 50/50 profit sharing agreement which encompasses the countries in Central and South America except Brazil. The AL-Sense Amniotic Fluid Diagnostic Leak Test to be called AmnioSense is a patented women's diagnostic product that is currently being sold in the United Kingdom, and has European Approval. It serves a huge market, and the birth rate in Latin America is three times the birth rate in North America and most of Europe. The target market for BMV/Easton has a population exceeding 200 million people. Sales in Latin America for pharmaceutical and diagnostic products are expected to grow at a rate five times that of North America and Europe as a result of a much higher birthrate in the region and other factors as well.

GynoFit Lactic Acid Gel Treatment For Bacterial Vaginosis (BV) in Mexico

Already approved in Mexico by the Swiss manufacturer who used a regulatory consultant to approve the product, Easton / BMV has an agreement in place including pricing from the manufacturer, and will place its first order within a few more weeks, pending finalization of the transfer of the registration to BMV. This product is expected to become a big selling product as it can treat Bacterial Vaginosis successfully without the use of harsh drugs.

These two approved products can be sold almost immediately in these countries pending final design and packaging. BMV/Easton has commenced discussions for distribution of the products with accredited distribution partners and is in discussions for another approved diagnostic product for Mexico and Latin America.

Dr. Jose Tiran Saucedo

Easton Pharmaceuticals previously announced the appointment of Dr. Jose Tiran Saucedo as the Founding Member of Easton Pharma's Medical/ Scientific Advisory Board. In this capacity Dr. Tiran is advising Easton Pharmaceuticals/BMV Medica and other regional partners in planning the Latin American launches of its suite of patented, exclusive women's health products over the coming months.

Dr. Tiran stated, "I am very excited to be part of the program for these soon-to-be-launched women's health and treatment products in the hope of providing to Latin American women the same choices they have in the US and Europe. We have a huge unmet medical need in Latin America for these kind of alternative diagnostic and treatment products. The vaginal discharge diagnostic test will facilitate a woman's ability to determine the causative agent; the natural lactic acid treatment gel will provide a new, non-toxic treatment option, and put Latin American women on a par with North American and European women. The professional version of this diagnostic test will also enable the gynecologist to increase the accuracy in the differential diagnosis of vaginal discharge, right in the gynecologist's office, something currently lacking in Latin America. The natural lactic acid gel treatment expected to launch in parallel with the diagnostic will be offered to women who test positive for bacterial infection and is a significant treatment option advance since it could obviate the need for potential use of antibiotics and further presence of bacterial resistance, so this is a promising and exciting development for the future of women's health."

Dr. Tiran further commented, "The amniotic fluid leak test will allow late-pregnancy women to have at their disposal a high-specificity/accuracy test at a fractional cost to other options on the market, with a very favorable ease-of-use component, thus contributing to an increase in the quality of perinatal care in Latin America. All these are new advances coming to Latin America, which I believe will catch on very quickly in both the community and the professional arenas."

Dr. Jose Tiran is a Thought Leader (KOL- Key Opinion Leader) in Gynecological Infectious Diseases, and is a Fellow of the American College of Obstetricians and Gynecologists. He has been a strong advocate over the years in women´s health worldwide. Also, Dr. Tiran has published numerous peer-reviewed papers on the subject, and is also board certified in Mexico, a member of multiple health societies, and holds numerous other prestigious positions in the field of Women's Health. Dr. Tiran is also well versed in other aspects of women's health such as sexually transmitted diseases, female sexual health, contraception, vaccines and gynecology and women´s health and wellbeing.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women's diagnostic products and two generic cancer products. Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"

. In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact:

Evan Karras
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

Copyright © 2016 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Easton Pharmaceuticals Letter to Shareholders and Update

Oct 07, 2015
OTC Disclosure & News Service

-

Easton Pharmaceuticals Letter to Shareholders and Update

TORONTO, ON--(Marketwired - Oct 7, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH)

Dear Fellow Shareholders,

We would like to respond to various questions directed to the company over the past few weeks and months and shed light on each initiative undertaken. As you are currently aware Easton Pharmaceutical has signaled its intent to becoming a more diversified company, operating in several different Industries and sectors. These sectors and initiatives as previously announced include its foray into the medical diagnostic and generic cancer drug industry for Mexico and Latin America, which represents a big opportunity to Easton and its shareholders. Easton would also like to update its shareholders of its initiatives in the medical marijuana industry in both the United States and Canada.

Easton - Common Sense Ltd. Exclusive Distributor Agreement
In March of this year, Easton Pharmaceuticals entered into a 50/50 profit-sharing partnership agreement with a partner whereby both companies currently possess exclusive distribution rights for the country of Mexico and the rest of Spanish speaking Latin America from Israel-based Common Sense Ltd. and their patented product lines known as VS-SENSE-OTC and VS-SENSE PRO, for the detection of Bacterial Vaginosis (BV) and Trichomonas and AL-SENSE Amniotic Fluid Leak Detection Test. Easton Pharmaceuticals has recently retained the services of Dr. Jose Tiran, a Thought Leader in women's health. Dr. Jose Tiran and Easton Pharmaceuticals believe the endeavor with BMV for the distribution rights within Mexico and Central and South America for the patented woman's diagnostic products from Common Sense Ltd., will be approved and able to deliver consistent, growing sales for Easton Pharmaceuticals commencing within the next 3 to 6 months.

Easton/BMV will initially launch in Mexico through medical sales reps and offer four products: the VS-Sense Vaginal Discharge diagnostic plus two treatment options: a European-approved natural lactic acid gel for when the diagnosis suggests Bacterial Vaginosis, and a terconazol-based yeast infection treatment for when the diagnostic suggests yeast infection. This is a similar triangle model Bayer HealthCare AG who has the exclusive European rights has recently launched in Europe.

Management believes this initiative represents a unique opportunity, which will reward all of its shareholders and investors. These products are currently protected by international patents with approximately 12 years remaining on the patent life and have CE Certification for selling and marketing in the EU obtained under the European Medical Device Directive 98/79/EC, Number IVD000256.

Ackerman Pharma S.A. de C.V., a highly respected Mexican pharmaceutical company, has been retained to file the regulatory documents to obtain regulatory approvals for the products in Mexico, and it is expected they will undergo a "fast-track" process through the use of government-approved third-party reviewers in order to shorten the normally long two-three year approvals process down to months.

The products are currently being marketed and sold in the United States through Prestige Brands in CVS, Walgreens and Rite-Aid Drug Stores under their own private label as well as under the leading Women's Health Care brands and throughout Canada in Shoppers Drug-Marts and Jean Coutu drug stores.

Easton and its partner BMV will be at the Mexican National Gynecology Conference in Mexico November 1-5, 2015 and will have meetings scheduled with leading gynecologist from around Mexico and other Latin American countries as part of a pre-launch marketing strategy. This is important for two reasons: awareness, leveraging the US and European launches and now being able to offer these products in Latin America; and as a source of increased revenues for the gynecologists one of the hot topics being discussed at the Gynecologist Conference next month. As different from their US and Canadian counterparts gynecologists in Mexico are permitted to sell products such as Easton/BMV's VS-Sense vaginal diagnostic test, the lactic acid treatment for Bacterial Vaginosis as well as the Amniotic Fluid Leak Test.

Generic Cancer Drugs Paclitaxel and Docitaxel - Biolyse Pharma

During the last quarter, Easton announced it had entered into an equal profit agreement to obtain the exclusive rights to distribute approved generic cancer drugs Paclitaxel and Docitaxel from Canadian pharmaceutical company, Biolyse Pharma for Mexico and parts of Central and South America.

Easton/BMV's regulatory filings company (Ackerman Pharma) believes the approval can be obtained by the end of 2015 or shortly into the New Year when Easton/BMV can then start to commence sales. Easton believes the potential market for these products for the company are in the tens of millions through sales and orders through the Mexican and various other governments.

Medicated Markets International
In January of this year, Easton Pharmaceuticals closed on an agreement with Medicated Markets International LLC, a private NY company where $110,000 was advanced to Medicated Markets who maintained they procured the rights to grower / cultivator licenses located in the City of Perris, California, (20 acres) Riverside county and one main growing location in Mendocino County, California with a total actual growing area of approximately 3 acres. Easton Pharmaceuticals subsequently terminated this agreement and has initiated an action in Superior court of Ontario Canada for the return of its funds plus damages from Medicated Markets and an individual for misrepresentation and possible fraud. Easton has since initiated discussions with other third parties in an attempt to enter into another agreement for the same assets.

AMFIL Technologies
Easton's ownership in AMFIL's mPact - GROzone Antimicrobial System is our entry into the infrastructure side of the Medical Marijuana industry on a business to business level. It is believed these products provide a clear cost saving benefit to various sized facilities of different industries including the medical marijuana, food and medical facilities. As a business product it also commands a high customized price tag in the range of 100k-150k per unit installed (based on size of area that's being serviced) and maintains quite high margins (over 50%) on initial product sales as well as maintenance contracts that follow initial installation. Residual income from the maintenance contracts will affect both the top and bottom lines. AMFIL is in the midst of completing a financial audit; Easton expects to recognize revenues from this investment and maintains an option to acquire up to 32 % of AMFIL as it relates to the installation of GROzone units that AMFIL has currently shipped and installed. Updates are expected shortly.

Easton's E-Cigarette,Vaporizer and CBD Directive
In November of 2014, Easton purchased a revenue generating Vaporizer business from Digital Shock Media where it has launched Vaporizer products through multiple websites, currently being run by Digital Shock and other third parties. This is a new developing industry where e-cigarettes continue to grow as an industry due to the elimination of second hand smoke release into the environment and other factors. Easton has generated wholesale sales through the efforts of Digital Shock media, but has since decided to use another company for the distribution of these products which includes possible sales channels in Mexico and Latin America. This business segment remains a niche market for the company while its main focus is with its Mexico and Latin America Initiatives.

Nutrashop Global Stores / OTC Products
In the first quarter of 2015, Easton entered into a distribution agreement with NutraShop Global Stores, Inc. for the distribution and sale of its 3 main OTC therapeutic products, (Viorra, Skin Renou HA and Kenestrin Pain Gel) through NutraShop's online store. NutraShop is an online wellness retailer of high quality Super Foods, vitamins and premium personal care products with a strong customer base across North America. Sales of the products were suspended during the last quarter as a result of a restructuring of the current agreement. NutraShop and Easton are currently undergoing discussions surrounding new developments for the white labeling of Easton's proprietary delivery matrix for distribution and sale of a new line of family wellness product through NutraPharm. NutraPharm is expected to take over the existing distribution agreement as Easton's new white label channel partner. NutraPharm is expecting to announce the new product(s) launch shortly. Easton's OTC products are currently being sampled and being evaluated by several other distributor options, which includes possible shelf space within select drug stores in Canada.

Financing / Dilution
Easton will require additional funding to execute on the packaging following the regulatory approval of all products in Mexico and Latin America in order to reach the marketing and sales stage. Funds have been allocated and set aside for all aspects of the woman's diagnostic products. Commitments have been received for additional financing through current directors and officers as well as other third parties which are contingent on the regulatory approvals.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women's diagnostic products and two generic cancer drugs Docitaxel and Paclitaxel. Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and rightfully holds an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"

. In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact:

Evan Karras /
Nunzio Valerie
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

Copyright © 2015 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Easton Pharmaceuticals Announces Finalized Agreement to Secure All of Spanish-Speaking Latin America, Adding to Its Mexico Rights for the VS-Senses Patented Women's Vaginal Health Diagnostic Test

Sep 15, 2015
OTC Disclosure & News Service

-

Easton Pharmaceuticals Announces Finalized Agreement to Secure All of Spanish-Speaking Latin America, Adding to Its Mexico Rights for the VS-Senses Patented Women's Vaginal Health Diagnostic Test

The VS-Sense Diagnostic Product Line Currently Holds Extended Patent Protection and Is Expected to Generate Well Over 100% Profit Margins for Easton/BMV; The Vaginal Health Test Is Currently Sold Throughout the United States and Canada and Has Recently Launched in Europe by Bayer; The Test Is Marketed in Each Territory Under Separate Brand Names

TORONTO, ON--(Marketwired - Sep 15, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces it has entered into a finalized agreement to secure all of Latin America for the patented vaginal health diagnostic test, and is expected to launch under the brand name EvaPro.

The agreement is an amendment to its previously executed 50 / 50 revenue sharing partnership agreement with BMV Medica SA de C.V. for an exclusive distribution agreement with Common Sense Ltd. of Israel to become the exclusive distributor in the country of Mexico for their patented woman's diagnostic Vaginal Health/Infection test, currently being sold throughout the United States, Canada and now Europe.

Both Easton and BMV are now pleased to announce they have obtained exclusive distribution rights for the rest of Latin America excluding Brazil from Israel-based Common Sense Ltd. and their patented product line known as VS-SENSE-OTC and VS-SENSE PRO, for the detection of Bacterial Vaginosis (BV) and yeast infections. BV is a common condition in which the natural balance of bacteria inside the vagina becomes disrupted. One in three women will get BV at some point in their lifetime, which demonstrates the huge market and revenue capabilities for the products. The products are currently protected by international patents with approximately 12 years remaining on the patent life and have CE Certification for selling and marketing in the EU obtained under the European Medical Device Directive 98/79/EC, Number IVD000256. The products are currently being sold within the United States and Canada with Bayer launching in Europe last month.

The products are currently being marketed and sold in the United States through Prestige Brands in CVS, Walgreens and Rite-Aid Drug Stores under their own private label as well as under the Monistat brand, and throughout Canada in Shoppers Drug-Mart and Jean Coutu.

Easton and BMV are well in the process of preparing regulatory filings in Mexico through contracted, industry respected regulatory consultants, Ackerman Pharma. Additional funds have been set aside towards branding and packaging. The regulatory approval in Mexico is anticipated within the next several months as the products are currently approved for sale in North America and Europe.

Easton / BMV believe the Mexican and other Latin American markets with their large population and ability to spend on personal health could approach the size of Europe or North America. Latin America represents approximately 20% of the world market in the pharmaceutical sector with a distinct bulge in the 15-45 yr. old demographic, added to its 400 plus million population and as such a larger proportion of premenopausal women than does the rest of North America.

The products will serve a market where no such products currently exist and is patent protected. Easton / BMV have decided to market under the EvaPro brand, and will market directly to obstetricians/gynecologists as well as entering into license agreements with various distributors and large drug store chains similar to the US model. The pricing per unit is expected to be in the same range as the US and Canada, approximately $18 per test kit which is considered affordable.

Easton and BMV anticipate launching the diagnostic test kit first, then quickly adding two treatment options: one for when the test offers negative results -- most likely a yeast infection (candida species), and one for when the test yields a positive result -- Bacterial Infection (BV). This is the "triangle model" which will be used in other markets, and entails bringing to market a probiotic lactic acid gel, (a natural treatment) for when the diagnosis is a bacterial infection. Easton / BMV believe this relatively new approach to diagnose and treat both yeast and bacterial vaginal infections may reduce substantially the need for antibiotic use, and also cut down substantially the time from first symptoms to successful diagnosis and treatment by up to several weeks. From a cost and health perspective this may be a major step forward in women's health.

The diagnostic kits will be available for personal use through pharmacies, and also in a slightly different format for the Doctor's offices.

Easton anticipates a minimum profit margin of 100% or slightly more once all expenses are factored in, and volumes to ramp up quickly since 1 in 3 women will at some point in their lives develop Bacterial Vaginosis (BV) and/or yeast infections.

In other developments: Easton and BMV are close to securing the rights to other diagnostic products and possible drugs which are currently approved for the Latin American markets which would allow for revenues to immediately commence following the closing of an agreement. Additional news and updates to shortly follow.

Evan Karras, CEO and director of Easton Pharmaceuticals stated, "We at Easton Pharmaceuticals are extremely pleased to have acquired and participate with BMV Medica for the additional rights to Spanish speaking Latin America for the exclusive distribution rights for its EvaPro OTC diagnostic product line and are currently working with BMV to bring to market the treatments that arise from the diagnosis, following US and European models. The reality is that most women sooner or later suspect and will acquire a yeast or bacterial infection and with many women this is a recurring event. This technology will allow them to determine the cause in a matter of seconds without the need to visit a doctor's office. The VS-Sense diagnostic products can easily and accurately diagnose the condition leading to a proper treatment."

About Common Sense Inc.

Common Sense Inc. is an internationally recognized company holding international patents for their VS-SENSE-OTC (consumer test) and VS-SENSE PRO (professional test) diagnostic products, for the detection of bacterial Vaginosis and Yeast Infections, conditions that effect many millions of women around the world. The products have FDA and Health Canada approvals, and CE Certification for selling and marketing in the EU obtained under the European Medical Device Directive 98/79/EC, Number IVD000256.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women's diagnostic products and two generic cancer products. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a company holding Medical Marijuana growing rights in California on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and rightfully holds an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"

(0)

(0)

Scroll down for more posts ▼